S2212 SCARLET
Description
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
This phase III trial compares the effects of shorter chemotherapy-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 8/28/2023
Location:
Lexington Medical Cancer Center